Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinasepositive nonsmallcell lung cancer

Author:        

Publisher: Spandidos Publications

ISSN: 2049-9469

Source: Molecular and Clinical Oncology, Vol.2, Iss.4, 2014-01, pp. : 567-570

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content